A Review of Mathematical Models for Leukemia and Lymphoma.
暂无分享,去创建一个
[1] Tom Lenaerts,et al. Dynamics of chronic myeloid leukemia under nilotinib therapy , 2010 .
[2] Ching-Hon Pui,et al. Modeling Mechanisms of In Vivo Variability in Methotrexate Accumulation and Folate Pathway Inhibition in Acute Lymphoblastic Leukemia Cells , 2010, PLoS Comput. Biol..
[3] Mithat Gönen,et al. Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials , 2012, Haematologica.
[4] D Grillot,et al. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. , 1996, Blood.
[5] Franziska Michor,et al. Successful Therapy Must Eradicate Cancer Stem Cells , 2006, Stem cells.
[6] Willi Jäger,et al. Modeling of asymmetric cell division in hematopoietic stem cells--regulation of self-renewal is essential for efficient repopulation. , 2009, Stem cells and development.
[7] Stefan Fruehauf,et al. Effect of CD34+ cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation , 2007, European journal of haematology.
[8] Holden T Maecker,et al. Development and dynamics of robust T-cell responses to CML under imatinib treatment. , 2008, Blood.
[9] Ingo Roeder,et al. An “Age” Structured Model of Hematopoietic Stem Cell Organization with Application to Chronic Myeloid Leukemia , 2009, Bulletin of mathematical biology.
[10] Bob Löwenberg,et al. Review Articles (434 articles) , 2008 .
[11] Dominik Wodarz,et al. Drug resistance in cancer: principles of emergence and prevention. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[12] F. Crauste,et al. Delay Differential Equations and Autonomous Oscillations in Hematopoietic Stem Cell Dynamics Modeling , 2012 .
[13] C. Tomasetti. A new hypothesis: imatinib affects leukemic stem cells in the same way it affects all other leukemic cells , 2011, Blood cancer journal.
[14] Doron Levy,et al. Dynamics and Potential Impact of the Immune Response to Chronic Myelogenous Leukemia , 2008, PLoS Comput. Biol..
[15] D. Levy,et al. Role of symmetric and asymmetric division of stem cells in developing drug resistance , 2010, Proceedings of the National Academy of Sciences.
[16] Karen M Page,et al. Mathematical models of the fate of lymphoma B cells after antigen receptor ligation with specific antibodies. , 2006, Journal of theoretical biology.
[17] Ignacio A. Rodriguez-Brenes,et al. Evolutionary dynamics of feedback escape and the development of stem-cell–driven cancers , 2011, Proceedings of the National Academy of Sciences.
[18] Martin C. Müller,et al. Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia. , 2013, Blood.
[19] Ching-Hon Pui,et al. A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia , 2002, Cancer Chemotherapy and Pharmacology.
[20] A. Marciniak-Czochra,et al. Mathematical Modeling of Leukemogenesis and Cancer Stem Cell Dynamics , 2012 .
[21] M. Matasar,et al. Advances in the diagnosis and management of lymphoma , 2012 .
[22] Fabien Crauste,et al. DISCRETE-MATURITY STRUCTURED MODEL OF CELL DIFFERENTIATION WITH APPLICATIONS TO ACUTE MYELOGENOUS LEUKEMIA , 2008 .
[23] A. Traulsen,et al. Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells , 2009, Haematologica.
[24] P. Ding,et al. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. , 2010, Leukemia research.
[25] D. Wodarz,et al. Combination of Two but Not Three Current Targeted Drugs Can Improve Therapy of Chronic Myeloid Leukemia , 2009, PloS one.
[26] M. Mackey,et al. Multistability in an age-structured model of hematopoiesis: Cyclical neutropenia. , 2011, Journal of theoretical biology.
[27] Ingo Roeder,et al. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications , 2006, Nature Medicine.
[28] Doron Levy,et al. Modeling Imatinib-Treated Chronic Myelogenous Leukemia: Reducing the Complexity of Agent-Based Models , 2008, Bulletin of mathematical biology.
[29] Philippe Rousselot,et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. , 2010, The Lancet. Oncology.
[30] M. Bodnar,et al. About a generalized model of lymphoma , 2012 .
[31] G. Núñez,et al. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2 , 1996 .
[32] Michael C Mackey,et al. A mathematical model of hematopoiesis--I. Periodic chronic myelogenous leukemia. , 2005, Journal of theoretical biology.
[33] A. Trumpp,et al. Therapy of chronic myeloid leukaemia can benefit from the activation of stem cells: simulation studies of different treatment combinations , 2012, British Journal of Cancer.
[34] J. Radich,et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia , 2010, Leukemia.
[35] Doron Levy,et al. A PDE Model for Imatinib-Treated Chronic Myelogenous Leukemia , 2008, Bulletin of mathematical biology.
[36] G. Chatta,et al. Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. , 1996, Blood.
[37] Franziska Michor,et al. Fitness Conferred by BCR-ABL Kinase Domain Mutations Determines the Risk of Pre-Existing Resistance in Chronic Myeloid Leukemia , 2011, PloS one.
[38] W. Evans,et al. Mechanistic mathematical modelling of mercaptopurine effects on cell cycle of human acute lymphoblastic leukaemia cells , 2005, British Journal of Cancer.